<DOC>
	<DOCNO>NCT02067169</DOCNO>
	<brief_summary>Resistance antiviral grow problem transplantation.that may concern 5 % patient treat cytomegalovirus ( CMV ) syndrome disease recent per-protocol study . This prevalence vary organ transplant degree viral replication immunosuppression . Less data available date real-life cohort patient , systematic survey resistance Europe US . Non response treatment concern large group patient result either emergence resistant strain ( virological resistance ) , inadequate dosage antiviral , high degree immunosuppression , poor CMV immune response . The respective clinical impact virological resistance clinical resistance ( pharmacological immunological origin ) graft outcome long-term survival patient never assess . High viral load persistent replication associate prolonged exposure antiviral know favor emergence resistant strain . Though epidemiology resistant strain , role multiple infection , impact various mutation degree resistance antiviral outcome remain study . Most study per-protocol study short-term study conduct limited population . There data real-life transplanted patient era enlarge prophylaxis except French survey cytomegalovirus resistance cohort open end 2006 . From first data collect 346 patient show 10,6 % prevalence non-response therapy 5,2 % virological resistance ( 6,1 % incidence one year 214 patient ) trend poorer outcome case virological resistance absence impact prophylaxis versus preemptive therapy , though large population prolong follow-up request fulfill objective . We therefore aim constitute prolong survey cohort CMV resistance large number patient prolong follow-up , gather data resistance antiviral real-life transplant patient organize data bank , This cohort continuum previous cohort start 2006 , grant Hospital Clinical Research Program Interregional ( PHRC ) , major objective prolong follow-up patient .</brief_summary>
	<brief_title>A French Cohort Transplant Recipients With CMV Infection : Risk Factors Antiviral Resistance Prophylaxis Era .</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>allograft recipient active CMV infection , patient previous cohort , without opposition biological collection sample willing participate , health insurance</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Transplantation</keyword>
	<keyword>CMV infection</keyword>
	<keyword>antiviral resistance</keyword>
</DOC>